These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2730684)

  • 1. Alterations in plasma amino acids and hepatic enzymes in the 4-pentenoic acid model of Reye's syndrome.
    Hart MA; Swisher JA; Caspers ML
    Biochem Pharmacol; 1989 May; 38(10):1696-8. PubMed ID: 2730684
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of mitochondrial fatty acid oxidation in pentenoic acid-induced fatty liver. A possible model for Reye's syndrome.
    Thayer WS
    Biochem Pharmacol; 1984 Apr; 33(8):1187-94. PubMed ID: 6712730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of 4-pentenoic acid-induced liver injury in rats by 16,16-dimethyl PGE2.
    Hidaka T; Inokuchi T; Nakamura Y; Kotegawa M; Sugiyama M; Ogura R
    Exp Mol Pathol; 1991 Oct; 55(2):135-42. PubMed ID: 1936211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Production of the features of Reye's syndrome in rats with 4-pentenoic acid.
    Glasgow AM; Chase HP
    Pediatr Res; 1975 Mar; 9(3):133-8. PubMed ID: 1121419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic metabolic alterations in rats treated with low-dose endotoxin and aspirin: an animal model of Reye's syndrome.
    Kilpatrick LE; Polin RA; Douglas SD; Corkey BE
    Metabolism; 1989 Jan; 38(1):73-7. PubMed ID: 2909830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of an animal model of a Reye-like syndrome caused by Margosa oil.
    Sinniah D; Schwartz PH; Mitchell RA; Arcinue EL
    Pediatr Res; 1985 Dec; 19(12):1346-55. PubMed ID: 4080457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resveratrol protects against experimental induced Reye's syndrome by prohibition of oxidative stress and restoration of complex I activity.
    Abdin A; Sarhan N
    Can J Physiol Pharmacol; 2014 Sep; 92(9):780-8. PubMed ID: 25162205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Free fatty acids in an animal model of Reye's syndrome.
    Deshmukh DR; Deshmukh GD; Shope TC; Radin NS
    Biochim Biophys Acta; 1983 Sep; 753(2):153-8. PubMed ID: 6615853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The biochemistry of Reye's syndrome.
    Brown RE; Forman DT
    Crit Rev Clin Lab Sci; 1982; 17(3):247-97. PubMed ID: 6127187
    [No Abstract]   [Full Text] [Related]  

  • 10. [Therapeutic effect of hepatoprotectors in experimental Reye syndrome].
    Vengerovskiĭ AI; Sukhodolo IV; Chuchalin VS; Arbuzov AG; Cherviakova MB; Mel'nik IuIu; Grishina EI; Fedoreev SA; Saratikov AS
    Eksp Klin Farmakol; 2000; 63(5):68-71. PubMed ID: 11109534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Animal models of Reye's syndrome.
    Deshmukh DR
    Rev Infect Dis; 1985; 7(1):31-40. PubMed ID: 3885365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microvesicular fatty liver in rats with resembling Reye's syndrome induced by 4-pentenoic acid.
    Sakaida N; Senzaki H; Shikata N; Morii S
    Acta Pathol Jpn; 1990 Sep; 40(9):635-42. PubMed ID: 2260472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of cytosolic and mitochondrial hepatic enzyme alterations in Reye's syndrome.
    Mitchell RA; Ram ML; Arcinue EL; Chang CH
    Pediatr Res; 1980 Nov; 14(11):1216-21. PubMed ID: 7454435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of L-carnitine supplementation in 4 pentenoic acid treated rats.
    Sugimoto T; Woo M; Nishida N; Araki A; Murakami K; Kobayashi Y
    Brain Dev; 1990; 12(4):417-22. PubMed ID: 2240462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical relationships between Reye's and Reye's-like metabolic and toxicological syndromes.
    Osterloh J; Cunningham W; Dixon A; Combest D
    Med Toxicol Adverse Drug Exp; 1989; 4(4):272-94. PubMed ID: 2671597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reye's syndrome: current concepts.
    Heubi JE; Partin JC; Partin JS; Schubert WK
    Hepatology; 1987; 7(1):155-64. PubMed ID: 3542776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Reye's syndrome].
    Wagner-Thiessen E
    Pathologe; 1985 Jul; 6(4):220-3. PubMed ID: 3900974
    [No Abstract]   [Full Text] [Related]  

  • 18. Masking by enzyme inhibitor of raised serum glutamate dehydrogenase activity in Reye's syndrome.
    Holt JT; Arvan DA; Mayer TK
    Lancet; 1983 Jul; 2(8340):4-7. PubMed ID: 6134899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total alpha-amino acid nitrogen quantification as prognosticator in Reye's syndrome.
    McArthur BS; Arcinue EL; Schultz GE
    Am J Dis Child; 1981 Aug; 135(8):765-6. PubMed ID: 7270523
    [No Abstract]   [Full Text] [Related]  

  • 20. Biochemical correlates of illness and recovery in Reye's syndrome.
    Trauner D; Sweetman L; Holm J; Kulovich S; Nyhan WL
    Ann Neurol; 1977 Sep; 2(3):238-41. PubMed ID: 617569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.